ArticleBMC gastroenterology2025
The development of a multimodal prediction model based on CT and MRI for the prognosis of pancreatic cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Bench to Bedside: The Path Toward Real-World Translation for Artificial Intelligence in Pancreatic Cancer Detection.Korean journal of radiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo develop and validate a hybrid radiomics model to predict the overall survival in pancreatic cancer patients and identify risk factors that affect patient prognosis.
methodsWe conducted a retrospective analysis of 272 pancreatic cancer patients diagnosed at the First Affiliated Hospital of Soochow University from January 2013 to December 2023, and divided them into a training set and a test set at a ratio of 7:3. Pre-treatment contrast-enhanced computed tomography (CT), magnetic resonance imaging (MRI) images, and clinical features were collected. Dimensionality reduction was performed on the radiomics features using principal component analysis (PCA), and important features with non-zero coefficients were selected using the least absolute shrinkage and selection operator (LASSO) with 10-fold cross-validation. In the training set, we built clinical prediction models using both random survival forests (RSF) and traditional Cox regression analysis. These models included a radiomics model based on contrast-enhanced CT, a radiomics model based on MRI, a clinical model, 3 bimodal models combining two types of features, and a multimodal model combining radiomics features with clinical features. Model performance evaluation in the test set was based on two dimensions: discrimination and calibration. In addition, risk stratification was performed in the test set based on predicted risk scores to evaluate the model's prognostic utility.
resultsThe RSF-based hybrid model performed best with a C-index of 0.807 and a Brier score of 0.101, outperforming the COX hybrid model (C-index of 0.726 and a Brier score of 0.145) and other unimodal and bimodal models. The SurvSHAP(t) plot highlighted CA125 as the most important variable. In the test set, patients were stratified into high- and low-risk groups based on the predicted risk scores, and Kaplan-Meier analysis demonstrated a significant survival difference between the two groups (p < 0.0001).
conclusionA multi-modal model using radiomics based on clinical tabular data and contrast-enhanced CT and MRI was developed by RSF, presenting strengths in predicting prognosis in pancreatic cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.